(NVS) Community Analysis from
Bulls REASONS TO BUY
|
93%
agree
16 votes
|
Alcon Acquisition |
|
80%
agree
5 votes
|
Novartis has strongest pipelines (50 new drugs in 5 years) |
|
100%
agree
2 votes
|
Undervalued |
Bears REASONS TO SELL
|
50%
agree
4 votes
|
FDA increasing regulations on contact with physicians |
|
20%
agree
5 votes
|
Diabetes drug delayed 1-2 years while clinical trials are conducted |
|
0%
agree
3 votes
|
Patent on key ingredients in Lotrel will expire within the year |
May 22, 2013
(Stock Blog Hub,
4/4/13)
Novartis (NVS) recently announced that the US Food and Drug Administration (FDA) rendered Breakthrough Therapy designation to its pipeline candidate LDK378.
The Breakthrough...(read more)
(Stock Blog Hub,
4/27/13)
The US Food and Drug Administration (FDA) recently released briefing documents ahead of the review by its Pulmonary-Allergy Drugs Advisory Committee of the New Drug Application (NDA)...(read more)
(Penny Stock DD,
3/22/13)
Novartis AG's (NVS: Quote) TOBI Podhaler has been approved by the FDA for the management of cystic fibrosis patients with Pseudomonas aeruginosa, a bacterium that causes lung infections.
Cystic...(read more)
Novartis AG (NVS) Company Overview
There is no analysis for NVS yet. But you can go to Wikinvest to help create one!
What's in this NVS analysis on Wikinvest...
- Corporate Overview
- History
- Business Segments
- Pharmaceutical Division (60% of sales, $30.6B in FY 2010)
- Sandoz (17% of sales, $8.5B in FY 2010)
- Consumer Health (12.3% of sales, $6.2B in FY 2010)
- Vaccines & Diagnostics (5.8% of sales, $2.9B in FY 2010)
- Research and Development ($9.1B in FY 2010)
- Trends and Forces
- Expanded Vaccine Manufacturing Capabilities
- Flu Pandemics/Epidemics
- New Focus on Biologics
- Patent expirations
- Novartis's generic presence, Sandoz
- Tightening FDA Regulations
- Competition
- References
